- Home
- WLGS vs GRI Comparison
WLGS vs GRI Comparison
Compare WLGS & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLGS
- GRI
- Stock Information
- Founded
- WLGS 1981
- GRI 2018
- Country
- WLGS Hong Kong
- GRI United States
- Employees
- WLGS N/A
- GRI N/A
- Industry
- WLGS Engineering & Construction
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- WLGS Consumer Discretionary
- GRI Health Care
- Exchange
- WLGS Nasdaq
- GRI Nasdaq
- Market Cap
- WLGS 3.0M
- GRI 3.4M
- IPO Year
- WLGS 2023
- GRI N/A
- Fundamental
- Price
- WLGS $0.05
- GRI $1.27
- Analyst Decision
- WLGS
- GRI Strong Buy
- Analyst Count
- WLGS 0
- GRI 2
- Target Price
- WLGS N/A
- GRI $22.00
- AVG Volume (30 Days)
- WLGS 144.7M
- GRI 256.9K
- Earning Date
- WLGS 08-19-2025
- GRI 08-18-2025
- Dividend Yield
- WLGS N/A
- GRI N/A
- EPS Growth
- WLGS N/A
- GRI N/A
- EPS
- WLGS N/A
- GRI N/A
- Revenue
- WLGS $3,951,649.00
- GRI N/A
- Revenue This Year
- WLGS N/A
- GRI N/A
- Revenue Next Year
- WLGS N/A
- GRI N/A
- P/E Ratio
- WLGS N/A
- GRI N/A
- Revenue Growth
- WLGS N/A
- GRI N/A
- 52 Week Low
- WLGS $0.03
- GRI $1.10
- 52 Week High
- WLGS $9.66
- GRI $30.43
- Technical
- Relative Strength Index (RSI)
- WLGS 45.71
- GRI 39.44
- Support Level
- WLGS $0.04
- GRI $1.15
- Resistance Level
- WLGS $0.08
- GRI $1.28
- Average True Range (ATR)
- WLGS 0.01
- GRI 0.13
- MACD
- WLGS 0.00
- GRI -0.07
- Stochastic Oscillator
- WLGS 17.37
- GRI 10.99
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED. WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, water supply and sewage disposal systems, and site project management.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.